[1] [1] SIEGEl R L, MILLER K D, JEMAL A. Cancer statistics, 2019 ［J］. CA-A Cancer Journal for Cliniclans, 2019, 69(1): 7-34.

[2] [2] KULIK L, HEIMBACH J K, ZAIEM F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis［J］. Hepatology, 2018, 67(1): 381-400.

[3] [3] WANG J, HA J, LOPEZ A, et al. Medicaid and uninsured hepatocellular carcinoma patients have more advanced tumor stage and are less likely to receive treatment［J］. Journal of Clinical Gastroenterology, 2018, 52(5): 437-443.

[4] [4] VALERY P C, LAVERSANNE M, CLARK P J, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide［J］. Hepatology, 2018, 67(2): 600-611.

[6] [6] KANG S, WARNER M, BELL S. Multiple functions for MCM2-7 ATPase motifs during replication initiation［J］. Molecular Cell, 2014, 55(5): 655-665.

[7] [7] YUAN Z, RIERA A, BAI L, et al. Structural basis of MCM2-7 replicative helicase loading by ORC-Cdc6 and Cdt1［J］. Nature Structural & Molecular Biology, 2017, 24(3): 316-324.

[8] [8] IZUMI M, MIZUNO T, YANAGI K I, et al. The MCM2-7-interacting domain of human mini-chromosome maintenance 10 (MCM10) protein is important for stable chromatin association and origin firing［J］. Journal of Biological Chemistry, 2017, 292(31): 13008-13021.

[9] [9] RAHIB L, SMITH B D, AIZENBERG R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States［J］. Cancer Research, 2014, 74(11): 2913-2921.

[10] [10] KOGURE N, YOKOBORI T, OGATA K, et al. Low expression of MCM2, MCM4, MCM10 is associated with gastric cancer progression and poor prognosis［J］. Anticancer Research, 2017, 37(1): 191-196.

[11] [11] CHANDRASHEKAR D S, BASHEL B, BALASUBRAMANYA S A H, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses ［J］. Neoplasia, 2017, 19(8): 649-658.

[12] [12] UHLEN M, FAGERBERG L, HALLSTROM B M, et al. Proteomics tissue based map of the human proteome［J］. Science, 2015, 347(6220): 1260419.

[13] [13] SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets［J］. Nucleic Acids Research, 2019, 47(D1): D607-D613.

[14] [14] ZHOU Y, ZHOU B, PACHE L, et al. Metascape provides a biologistoriented resource for the analysis of systems-level datasets ［J］. Nature Communications, 2019, 10(1): 1523.

[15] [15] LI Z, XU X Z. Post-translational modifications of the mini-chromosome maintenance proteins in DNA replication［J］. Genes Basel, 2019, 10(5): E331.

[16] [16] LIU Z, LI J, CHEN J, et al. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression［J］. BMC Cancer, 2018, 18(1): 200.

[17] [17] BROSH R M J R,TRAKSELIS M A. Fine-tuning of the replisome: MCM10 regulates fork progression and regression［J］. Cell Cycle, 2019, 18(10): 1047-1055.

[19] [19] ZHOU Q, REN J B, HOU J X, et al. Co-expression network analysis identified candidate biomarkers in association with progression and prognosis of breast cancer［J］. Journal of Cancer Research and Clinical Oncology, 2019, 145(9): 2383-2396.

[20] [20] SAMAD A, HAQUE F, NAIN Z, et al. Computational assessment of MCM2 transcriptional expression and identification of the prognostic biomarker for human breast cancer［J］. Heliyon, 2020, 6(10): e05087.

[23] [23] DONGNA S U. MCM7 affects the cisplatin resistance of liver cancer cells and the development of liver cancer by regulating the PI3K/Akt signaling pathway［J］. Immunopharmacology and Immunotoxicology, 2022, 44(1): 17-27.

[24] [24] YU S, WANG G, SHI Y, et al. MCMs in cancer: prognostic potential and mechanisms［J］. Analytical Cellular Pathology, 2020, 2020(9): 1-11.